Incretins: A new treatment option for type 2 diabetes?

Netherlands Journal of Medicine

Volumn 65, Issue 2, 2007, Pages 60-64

  Geelhoed Duijvestijn, P H L M ^a  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

DDP 4 inhibitors; GLP I analogues; GLP receptor agonist; Incretins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PROGLUCAGON; SITAGLIPTIN; SOMATOSTATIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ADD ON THERAPY; ADRENERGIC STIMULATION; APOPTOSIS; AREA UNDER THE CURVE; BODY WEIGHT; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; ENZYME INHIBITION; EXERCISE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET CELL; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIDE EFFECT; SOMATOSTATIN RELEASE; STOMACH EMPTYING; WEIGHT GAIN; WEIGHT REDUCTION;

ADENOSINE DEAMINASE; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; RECEPTORS, GLUCAGON; SATIETY RESPONSE;

EID: 33847359658     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-I 7-36: a physiological incretin in man. Lancet 1987;2:1300-4.
2. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Nijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996;271:E808-13.
3. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regu Integr Comp Physiol 2000;279:R1499-54.
4. Fehse FC, Trautmann ME, Holst JJ, et al. Effects of exenatide on first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. Diabetes Care 2004;53(suppl 1):A82.
5. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40.
6. Gutzwiller J P, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004;89:3055-61.
7. Osaka T, Endo M, Yamakawa M, Inoue S. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 2005;26:1623-31.
8. MacLusky NJ, Cook S, Scrocchi L, et al. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 2000;141:752-62.
9. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol 2001;E155-61.
10. Bregenholt S, Moldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005;330:577-84.
11. Mentlein T, Gallwitz B, Schmidt WE. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide_1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35.
12. Buse JB, Henry RR, Han J, et al. Effects of exenatide (Exendin-40 on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.
13. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
14. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
15. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-47.
16. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycemic control and weight in over-weight metformin treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006;8:419-28.
17. Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulfonylureas with or without metformin. Diabetes Metab Res Rev 2006;22:483-91.
18. Zinman B, Hoogwerf B, Garcia SD, et al. Safety and efficacy of exenatide in patients with type 2 diabetes mellitus (T2DM) using thiazolidinediones (TZDs) or TZDs and metformin (MET). Diabetes 2006;55(Suppl 1):A28 Abstract 117-OR.
19. McCall A, Cox DJ, Brodows R, et al. Reduced glycemic variability and risks for hypoglycemia with exenatide therapy as compared to insulin glargine. Diabetologia 2006;48(Suppl 1):A288, Abstract 794.
20. Heine RJ, van Gaal LF, Johns D, Mihm MJ, Widel MH, Browdows RG, for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005;143:559-69.
21. Hood RC. Exenatide (EXE) use in T2DM with A1C≤7%. Diabetes 55 (Suppl 1): Abstract 488-P 2006.
22. Kim D, MacConell L, Zhang D, Schnabel C, Taylor K, Li W-I, Trautmann M. Safety and effects of a once-weekly long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes. Diabetologia 2006;55(Suppl 1)A116: Abstract 487-P.
23. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and betacell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004:53:1187-94.
24. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Liraglutide Dose-Response Study Group. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med 2005;22:1016-23.
25. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR, for the NN2211-1310 116 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-42.
26. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915-21.
27. Nauck MA, Hompesch M, Filipicazak R, Le TD, Zdravkovic M, Gumprecht J for the NN2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006; 114:417-23.
28. Visbell T, Zdravkovic M, Le-Thi T, et al. Liraglutide significantly improves glycemic control and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetes. Diabetes 55(Suppl 1)27-28 Abstract 115-OR.
29. Pratley RE, Jauffret-Kamel S, Galbreath, Holmes D. Twelve week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-8.
30. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25:869-75.
31. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidylpeptidase IV inhibitor LAF 237 in metformin treated patients with type 2 diabetes. Diabetes Care 2004:27:2874-80.
32. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40.
33. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88.
34. Herman GA, Bergman A, Yi B, Kipnes M, for the Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006;22:1939-47.
35. Xu L, Stein P, Brazg R, Sanchez M, Dalla Man C, Cobelli C. Sitagliptin, a novel dipeptidyl peptidase-4 inhibitor, improved B-cell function in patients with type 2 diabetes when added to metformin monotherapy. IDF 2006 Abstract 868.